Yahoo Finance·2025-10-31 14:03Core Insights - Metsera Inc. (NASDAQ:MTSR) has reached an all-time high due to a bidding war between Pfizer Inc. and Novo Nordisk, with Metsera's stock price increasing by 22.06% to $63.73 after hitting a 52-week high of $66.10 [1][2] Group 1: Bidding War Details - Novo Nordisk has made an $8.5 billion offer for Metsera, which is 16% higher than Pfizer's $7.3 billion offer, despite Pfizer having secured Metsera's approval for the merger previously [2] - Pfizer is preparing to sue both Metsera and Novo Nordisk, claiming that the acquisition attempt violates their agreement and antitrust laws [3] Group 2: Company Background and Market Context - Metsera is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and cardiometabolic diseases, positioning itself in the growing weight-loss drug market [5] - Pfizer had previously halted a clinical trial for its weight loss treatment, danuglipron, due to concerns over potential drug-induced liver failure [4]